Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03669861 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Abatacept in IgG4-Related Disease
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03669861: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT03669861 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03669861, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a Phase 2, single center, proof of concept clinical trial in subjects with active IgG4-Related Disease (IgG4-RD). Approximately 10 subjects with active IgG4-RD will be enrolled into this study. Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks).
Interventions
- DRUG Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-11-13 |
| Est. Completion | 2020-11-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03669861
The ClinicalTrials.gov registry entry for NCT03669861 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abatacept is the first listed.
NCT03669861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03669861 about?
NCT03669861 is a clinical study titled "Safety and Efficacy of Abatacept in IgG4-Related Disease". This is a Phase 2, single center, proof of concept clinical trial in subjects with active IgG4-Related Disease (IgG4-RD). Approximately 10 subjects with active IgG4-RD will be enrolled into this study. Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks).
What is the current status of trial NCT03669861?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2018-11-13. Estimated completion is 2020-11-10.
What interventions are being tested in trial NCT03669861?
The interventions under investigation include: Abatacept (DRUG).
Who is sponsoring clinical trial NCT03669861?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.